Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
about
Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implicationsMy approach to the treatment of sclerodermaSystemic Sclerosis and Malignancy: A Review of Current DataScleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvementRecent advances in the genetics of systemic sclerosis: toward biological and clinical significanceIdiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.Small Cell Lung Cancer in a 20-year-old Non-Smoking Man with Systemic Sclerosis.Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.Raynaud's phenomenon, inflammatory arthritis, and weight loss: pay attention to the man behind the curtain.Review: cancer-induced autoimmunity in the rheumatic diseases.Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.Squamous Cell Lung Cancer Associated With Systemic Sclerosis.Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.RNA polymerase III repression by the retinoblastoma tumor suppressor protein.PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.RNA Polymerase III Advances: Structural and tRNA Functional Views.Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome - description of two cases.Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer.Recurrent metastatic breast cancer presenting with paraneoplastic scleroderma.Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.Molecular and cellular basis of scleroderma.The role of the acquired immune response in systemic sclerosis.Cytokines in the immunopathology of systemic sclerosis.Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course.Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment.Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.An update on biomarker discovery and use in systemic sclerosis.Association of the autoimmune disease scleroderma with an immunologic response to cancer.Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.Scleroderma-related interstitial lung disease.RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan.Why target the tumor stroma in melanoma?Anti-RNA polymerase III antibody positive limited cutaneous systemic sclerosis with cryoglobulin-induced digital gangrene.
P2860
Q24605267-DE2485A1-2529-4E0D-9D08-B2A9C623674CQ24618843-6FA9CB08-2562-4DD2-ACE4-90E35AF2C129Q26740318-4E223E44-4C21-4B05-8513-4D2C3A3B3208Q26995764-CA7FD6E0-8453-44D9-96BB-7809275CC5E4Q28088499-735A3CDA-F14A-4994-AC7C-CF2029E64C43Q30252086-EA7D1182-D84A-47D8-AE1E-3F6227B37180Q33894752-9E38148A-1D42-4299-A9A5-05F65BBEE80EQ34107962-2B16F96A-0AA1-47A7-9C0F-0C66E062360BQ34128485-ADF7C271-A66E-4B6C-BC9A-908461DDD979Q34666066-46BAC34F-8563-4BFF-9035-E5A3A8912B91Q34721223-649F0269-1FFC-41BB-8CB5-4F3FE9C0CDC8Q35454043-59B57395-BE3C-4997-84B6-7F475882B219Q36130646-BF666C67-DD25-4AC0-B67E-BDFB3AD3C877Q36276815-67AEBC34-D351-4380-8B21-B63A2F69DA9AQ36546331-7002863B-CCB1-4D37-AF59-DDB9582FAF28Q36788809-02BC01ED-B9AE-4DD9-8E4C-3758F32D284DQ36944786-0D0D591C-3D4A-49A7-8588-EF11CA07CEAAQ37031224-13F070A5-7881-4469-B838-A7AD76DCD087Q37100264-F4279483-10D9-4821-938F-82A1D22C6B14Q37226360-2A8852AB-7BFC-4A85-B63E-8C09CAAF25C7Q37451165-1DE1A7F5-B6B3-497E-9085-591379671B06Q37656951-C0EE6D2C-946D-4361-B38A-D4BE74C51780Q37690735-78951550-8EF9-4CC8-A6F4-D9DC401318F2Q38230276-1C903174-D234-49A1-ADB9-DA531579A599Q38543690-3A4971EA-DB94-4DE2-B951-698FDFA1AF8EQ38543692-BE96D822-D787-431E-AD80-704E37115091Q38630663-52E4F606-0AF7-4FCA-BD3A-734BD997B0A5Q38952138-9F8CCFCA-4752-4491-932A-16370773668CQ38979780-95A90819-0B28-4362-B088-DC6A9E442C1BQ39021248-FC4DB7FC-6CC5-4882-BE34-E906114C8FF2Q39044741-C480B179-6404-4E4C-86FD-D836A0E42694Q39450087-1B563FBC-13A2-4EB2-8737-9F4A613FC3A8Q40043509-ECF37011-9B41-4842-994E-BCC8469FD7C2Q40241820-4C85429A-0C46-4E5B-A51E-891A4341409AQ40656308-78A8A9B8-2CF7-42A0-98C4-DBF6CA15D688Q41105228-EB2AE130-72E0-4CA4-9316-9B60F841B448Q41187671-3087BD8E-4AD7-431E-AB17-52FC41281B5CQ44584276-86ACA0F3-7B52-43E7-B384-81960C8E82C6Q47645232-A5C2449B-525C-4329-A1EB-84E3B3B90338Q48501021-594DE28B-ADD8-4E73-A64F-069F0394065E
P2860
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Close temporal relationship be ...... A polymerase I/III antibodies.
@ast
Close temporal relationship be ...... A polymerase I/III antibodies.
@en
Close temporal relationship be ...... A polymerase I/III antibodies.
@nl
type
label
Close temporal relationship be ...... A polymerase I/III antibodies.
@ast
Close temporal relationship be ...... A polymerase I/III antibodies.
@en
Close temporal relationship be ...... A polymerase I/III antibodies.
@nl
prefLabel
Close temporal relationship be ...... A polymerase I/III antibodies.
@ast
Close temporal relationship be ...... A polymerase I/III antibodies.
@en
Close temporal relationship be ...... A polymerase I/III antibodies.
@nl
P2093
P2860
P356
P1476
Close temporal relationship be ...... NA polymerase I/III antibodies
@en
P2093
Ami A Shah
Antony Rosen
Fredrick Wigley
Livia Casciola-Rosen
P2860
P304
P356
10.1002/ART.27549
P577
2010-09-01T00:00:00Z